Glaucoma Therapeutics Market to be worth US$ 7,600 Mn By 2026, Increase in prevalence and incidence of diabetic disorders to drive the market

Albany NY, United States: Transparency Market Research has published a new report titled, “Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”.

Albany NY, United States: Transparency Market Research (TMR) has published a new report titled, Glaucoma Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2018–2026”. According to the report, the global glaucoma therapeutics market was valued at US$ 5,932.6 Mn in 2017 and is projected to expand at a CAGR of 2.9% from 2018 to 2026. Increase in prevalence and incidence of diabetic disorders, rise in geriatric population, improved health care as well as health care infrastructure, and introduction of combination therapies are anticipated to propel the global market from 2018 to 2026. North America and Asia Pacific are expected to dominate the global glaucoma therapeutics market in the next few years. This is attributed to the well-established reimbursement policies by private and government health care institutes. According to the American Glaucoma Society, over 27 million people are affected with glaucoma in the U.S. alone. Players operating in the global glaucoma therapeutics market have made a series of strategic acquisitions, which contributes to the increase in their market share.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=16406

Prostaglandins Segment to Capture Largest Market Share

The report offers detailed segmentation of the global glaucoma therapeutics market. Based on drug class, the prostaglandins segment dominated the market in terms of revenue, as these are the most widely used topical eye drops, followed by beta blockers and combination medication. The combination medication and beta blockers segments are projected to expand at a rapid pace during the forecast period compared to the prostaglandins segment. Low cost of beta blockers and advantage of two drugs in combination medication are the factors contributing to the growth of these segments.

The prostaglandins segment is expected to grow at a sluggish pace due to high cost and increase in prescriptions for beta blockers and combination medication. The beta blockers segment is dominated by a number of generic brands. However, the cholinergics and alpha agonists segments are expected to experience steady growth during the forecast period. Additionally, increase in awareness about the diagnosis and treatment of glaucoma and growth of the generic drugs market drive the glaucoma therapeutics market.

Request for Analysis of COVID-19 Impact on Glaucoma Therapeutics Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=16406

Specialty Clinics Segment to Expand at Rapid Pace

The hospitals segment accounted for significant market share in 2017, followed by the specialty clinics segment. The specialty clinics segment is anticipated to expand at a high CAGR during the forecast period. Affordable health care facilities provided in specialty clinics is the major factor fueling the growth of the segment. Specialty clinics is the second leading segment, as the primary detection and treatment of glaucoma are carried out at hospitals. Ambulatory surgical centers is a small segment of the market and is expected to witness steady growth during the forecast period.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=16406

Asia Pacific Market to be Driven by Rise in Prevalence of Diabetes and High Adoption of Generic Drugs

In terms of revenue, North America dominated the global glaucoma therapeutics market in 2017. However, the region is estimated to lose market share in the near future, owing to loss of patents and emerging low cost generics. Asia Pacific held a major share of the market in 2017, attributed to high prevalence of diseases, increase in health care spending, and rise in geriatric population. The market in Asia Pacific is expected to expand at a high CAGR during the forecast period from 2018 to 2026. Large patient pool and rise in awareness about glaucoma are the key factors driving the glaucoma therapeutics market in the region. The booming medical tourism driven by rise in government support and incorporation of different schemes to avail better treatment for patients is also likely to propel the market in Asia Pacific. Increase in the number of localized manufacturers and strengthening of distribution network in Asia Pacific due to growing economy offer significant investment opportunities for market players.

Buy now Glaucoma Therapeutics Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=16406&ltype=S

Fragmented Market Dominated by Allergan plc and Novartis AG

The report also provides profiles of leading players operating in the global glaucoma therapeutics market. Novartis AG and Allergan plc are major players operating in the market, offering products with proprietary technologies. Other players include Merck and Co., Inc., Pfizer, Inc., Santen Pharmaceuticals Co. Ltd., Valeant Pharmaceuticals International, Inc., and Aerie Pharmaceuticals, Inc.

The global glaucoma therapeutics market is characterized by the presence of major companies competing against each other primarily in terms of limited side effects, product efficacy, prolonged action, robust pipeline, and operational base. These players focus on launching new and improved therapies and are making significant investments in R&D to gain market share.

More Trending Reports by Transparency Market Research:

Body Fat Reduction Market Studies show that the best way to achieve an ideal amount of body fat varies from one person to the next. This means that what works for someone else may not help another person reduce their body fat percentage, and vice versa. When user want to lose weight for improved health or enhanced athletic performance, body fat reduction is the ultimate goal. Generally, active individuals or athletes wanting for body fat reduction fall into one of two categories.

Healthcare Assistive Robot Market Healthcare assistive robots will be robots utilized in the healthcare industry that could detect, and perform activities in advantage of individuals with incapacities and seniors. Quickly developing geriatric populace coupled with a flood in rate of constant problems is relied upon to drive the healthcare assistive robots market in the future. The healthcare assistive robot market is probably going to develop a record of expanding rate of stroke coupled with the increasing instances of wounds and mishaps across the globe.

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Rohit Bhisey
Transparency Market Research
State Tower,
90 State Street,
Suite 700,
Albany NY - 12207
United States
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: https://www.transparencymarketresearch.com/